GlycanAge and ExoEarth partner on biological age testing in Japan

GlycanAge and ExoEarth Corp. have signed an MOU to expand glycan-based biological age testing in Japan and launch joint aging research. The collaboration links GlycanAge’s immune-health biomarkers with ExoEarth’s exosome science as Japan’s longevity market keeps growing.

Why it matters: - The partnership aims to make biological age testing more available in Japan, where preventive and personalized longevity care already has strong demand. - The collaboration connects two research areas that could help track aging more precisely: glycan biomarkers and exosome biology. - The companies plan to use the work to support a broader model of healthy longevity built around measuring and monitoring age-related health changes.

What happened: - GlycanAge and ExoEarth Corporation announced a strategic collaboration on August 20, 2026. - The agreement was formalized through a Memorandum of Understanding. - The collaboration covers both commercial expansion and joint scientific research. - GlycanAge plans to expand access to its glycan-based biological age testing across Japan. - ExoEarth develops the EXOCURE® platform in Japan.

The details: - The joint research program will be designed as a longitudinal study. - GlycanAge testing will be used to evaluate changes over time in biological-age and immune-related indicators associated with the EXOCURE® program. - Details on participant numbers, measurement intervals, intervention conditions and research governance will be set after scientific, medical, ethical and regulatory review. - GlycanAge says its flagship at-home test measures inflammaging and immune system health, including changes that can appear before standard bloodwork. - The company says its platform is built on more than 30 years of glycoscience research and more than 350 peer-reviewed publications. - ExoEarth says the EXOCURE® platform is based on extracellular vesicles derived from stem cells obtained from human exfoliated deciduous dental pulp and combines clinical collaboration, biological data and longevity research. - Nikolina Lauc, CEO of GlycanAge, said Japan is one of the world’s most advanced longevity markets and that combining glycan biomarkers with ExoEarth’s exosome expertise opens new avenues for understanding aging. - Takashi Nishihira, CEO of ExoEarth Corporation, said his own long-term GlycanAge tracking shaped his view that age can serve as an indicator for managing health. - Nishihira said the companies want to promote a healthy-longevity cycle of measure, understand, act and measure again. - More information is available at glycanage.com and exoearth.co.jp.

Between the lines: - The deal pairs a commercial rollout with a research agenda, which can help each company build credibility while expanding its footprint. - The study design is still unsettled, so the scientific value will depend on the final protocol and regulatory approvals. - Japan is being used as both a market entry point and a test bed for longevity science, which suggests the companies see potential for wider international expansion later.

What's next: - The companies will complete scientific, medical, ethical and regulatory review before finalizing research details. - GlycanAge and ExoEarth are expected to define the study population, testing cadence and governance framework next. - The collaboration will move forward on both Japan market expansion and the joint research program if the necessary approvals are secured.

The bottom line: - GlycanAge and ExoEarth are betting that combining biomarker testing with exosome research can accelerate both commercial adoption and aging science in Japan.